Organogenesis (NASDAQ:ORGO) Issues Earnings Results, Beats Estimates By $0.11 EPS

Organogenesis (NASDAQ:ORGO) posted its quarterly earnings data on Tuesday. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.11, Zacks reports. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The company had revenue of $115.18 million during the quarter, compared to analyst estimates of $109.59 million. During the same quarter last year, the company earned $0.02 EPS. Organogenesis updated its FY 2024 guidance to EPS.

Organogenesis Stock Down 4.5 %

ORGO traded down $0.18 during trading on Friday, hitting $3.83. 191,720 shares of the company’s stock traded hands, compared to its average volume of 822,942. The company’s 50 day simple moving average is $2.97 and its two-hundred day simple moving average is $2.81. The company has a current ratio of 3.09, a quick ratio of 2.42 and a debt-to-equity ratio of 0.21. Organogenesis has a 12-month low of $2.16 and a 12-month high of $4.70. The stock has a market capitalization of $507.78 million, a price-to-earnings ratio of -63.50 and a beta of 1.60.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.